Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Peter C. Enzinger, M.D.

Co-Author

This page shows the publications co-authored by Peter Enzinger and Harvey Mamon.
Connection Strength

1.517
  1. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021 Apr; 17(10):1143-1153.
    View in: PubMed
    Score: 0.230
  2. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response. Ann Nucl Med. 2018 Apr; 32(3):165-174.
    View in: PubMed
    Score: 0.186
  3. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer. Dis Esophagus. 2017 Jul 01; 30(7):1-8.
    View in: PubMed
    Score: 0.179
  4. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer. BMC Cancer. 2016 07 13; 16:468.
    View in: PubMed
    Score: 0.167
  5. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013; 18(3):281-7.
    View in: PubMed
    Score: 0.132
  6. Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma. Pract Radiat Oncol. 2012 Oct-Dec; 2(4):e89-e94.
    View in: PubMed
    Score: 0.124
  7. Phase II cisplatin, irinotecan, cetuximab and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):4064.
    View in: PubMed
    Score: 0.083
  8. Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). Pharmacogenet Genomics. 2021 12 01; 31(9):215-220.
    View in: PubMed
    Score: 0.061
  9. Florid Foreign Body-type Giant Cell Response to Keratin Is Associated With Improved Overall Survival in Patients Receiving Preoperative Therapy for Esophageal Squamous Cell Carcinoma. Am J Surg Pathol. 2021 12 01; 45(12):1648-1660.
    View in: PubMed
    Score: 0.061
  10. Outcomes of trimodality CROSS regimen in older adults with locally advanced esophageal cancer. Eur J Surg Oncol. 2021 10; 47(10):2667-2674.
    View in: PubMed
    Score: 0.058
  11. Contribution of FDG-PET/CT to the management of esophageal cancer patients at multidisciplinary tumor board conferences. Eur J Radiol Open. 2020; 7:100291.
    View in: PubMed
    Score: 0.057
  12. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35(32):3671-3677.
    View in: PubMed
    Score: 0.046
  13. The 3-Hole Minimally Invasive Esophagectomy: A Safe Procedure Following Neoadjuvant Chemotherapy and Radiation. Semin Thorac Cardiovasc Surg. 2015; 27(2):205-15.
    View in: PubMed
    Score: 0.039
  14. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014 Jun; 19(6):637-8.
    View in: PubMed
    Score: 0.036
  15. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011 May 20; 29(15_suppl):4003.
    View in: PubMed
    Score: 0.029
  16. Gastric adenocarcinoma treated with radiation with or without epirubicin-based chemotherapy: Evaluation of radiation-induced liver disease. J Clin Oncol. 2011 Feb; 29(4_suppl):110.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.